4.5 Review

Valuing vaccines: Deficiencies and remedies

Journal

VACCINE
Volume 33, Issue -, Pages B29-B33

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.03.023

Keywords

Benefit-cost analysis; Cost-effectiveness analysis; Valuation

Funding

  1. WHO
  2. Sanofi Pasteur
  3. Merck

Ask authors/readers for more resources

Current evaluation models for the value of vaccines typically account for a small subset of the full social and economic benefits of vaccination. Health investments yield positive economic benefits via several channels at the household, community, and national levels. Underestimating, or worse, not considering these benefits can lead to ill-founded recommendations regarding the introduction of vaccines into immunization programs. The clear and strong links between health and wealth suggest the need to redesign valuation frameworks for vaccination so that the full costs may be properly weighed against the full benefits of vaccines. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available